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Abstract  
 
Many traditional medicinal herbs from Burkina Faso are used to treat arterial hypertension (HTA). Among them, 
Anogeissus leiocarpus (A. Leiocarpus) which is well known and widely used in Burkina traditional medicine. Herein we 
assess the effects of dichloromethane fraction from A. leiocarpus stem bark (ALF), selected as the most active on cyclic 
nucleotide phosphodiesterases (PDEs) and characterized its specificity towards purified vascular PDE1 to PDE5 isoenzymes 
and study its effects on a vascular model.  ALF potently and preferentially inhibits (IC50=1.6 ± 0.6 µg/mL) the calmodulin-
dependent phosphodiesterase PDE1, being mainly present in vascular smooth muscle and preferentially hydrolyses cGMP. In 
the same range (IC50 =2.8 ±0.2 µg/ml) ALF inhibits PDE2, a cGMP-activated enzyme that is only present in endothelial cells 
and hydrolyses both cAMP and cGMP. PDE5, which specifically hydrolyses cGMP and which mainly contributes to cGMP 
hydrolysis is also potently inhibited by ALF (IC50=7.6±3.5 µg/ml). The potencies of ALF on cAMP hydrolyzing isoenzymes 
was lesser, being more effective on PDE4 (IC50= 17.6±3.5 µg/ml) than on PDE3 (60.9 ± 1.8 µg/ml). Since the major effect of 
ALF were against cGMP hydrolysis and since cGMP is implicated in endothelium-dependent relaxation, the endothelium-
dependent vasorelaxation was studied on isolated porcine coronary arteries rings pre-contracted with U46619. The 
endothelium-dependent vasorelaxation is significantly inhibited by Nω-nitro-L-arginine (LNA 300 µmol/L, an inhibitor of 
endothelial NO synthase), but not affected by charybdotoxin (CTX, 100nM) plus apamin (APA, 100nM) (two inhibitors of 
EDHF-mediated responses). The combination of 4-aminopyridine (4-AP, 1 mmol/L, inhibitor of voltage-dependent 
potassium channels, Kv) plus baryum (Ba2+, 30 µmol/L, inhibitor of the potassium channels with entering correction, Kir) plus 
ouabain (3 µmol/L, inhibitor of ATPase Na+/K+ channels) partially inhibits endothelium-independent vasorelaxant effect. 
This endothelium-independent relaxant effect was also sensitive to combination of 1H-[1,2,4]-oxadiazole-[4,3-α]-quinoxalin-
1-one (ODQ, 10 µM, soluble guanylyl cyclase inhibitor) and N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinoline 
sulfonamide dihydrochloride (H89, 100 nM, Protein Kinase A inhibitor). Taken together, these results indicate that ALF is a 
powerful vasodilator modulated by the formation of NO from endothelium, but also act by directly relaxing the vascular 
smooth muscle cells, by inhibiting cGMP hydrolyzing PDEs (PDE1, PDE2 and PDE5)  and to a lesser extend on cAMP 
degradation (PDE3 and PDE4), cAMP and cGMP being second messengers involved in vascular relaxation. 
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Introduction 
 
According to the World Health Organization (OMS., 2002), more than 80% of the African populations have 
recourse to traditional medicine and pharmacopeia for the needs of primary health. In Burkina Faso, following the example of 
other developing countries, medicinal plants are used in the treatment of various pathologies among which the arterial 
hypertension (Nacoulma /Ouédraogo, 1996; Yao, 2005). Among these plants, A. leiocarpus (D.C.) Guill. and Perr. 
(Combretaceae) is widely used for some of its properties such as pest-destroying (Okpekon et al. 2004), trypanocides 
(Shuaibu et al. 2008) and antifungal (Batawila et al. 2005). Recently, antibacterial activity of terpenoidal fractions from A. 
leiocarpus have been shown (Mann et al., 2007). We have demonstrated an anti-HTA property of the aqueous extract of A. 
leiocarpus (Belemnaba, 2007., Ouédraogo et al., 2008). Since, it was demonstrated that some plant extracts inhibit cyclic 
nucleotide phosphodiesterase (PDE) isoenzymes (Lobstein et al. 2002) and that (PDE1 to PDE5) play a major role in 
vascular contraction (Lobstein et al. 2002; Lugnier 2006). So this study evaluated the effects of the dichloromethanolic 
fraction (ALF) of A. leiocarpus stem bark on the activity of purified vascular PDE isoenzymes (PDE1-PDE5) and on porcine 
coronary arteries vasorelaxation.  
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Materials and Methods  
Plant extract 
 
Stem barks of A. leiocarpus were collected in May 2006 in the area of Loumbila (zone of savanna), locality located  
at 20 km in the East of Ouagadougou (Burkina Faso). Voucher specimen (N°1544) was deposited at the herbarium of the 
Department of Forest Production, National Centre for Scientific and Technological Research, Ouagadougou Burkina Faso. 
The collected sample was air-dried deprived of solar light, dust and was powdered. The extract of ALF was prepared starting 
from the powder of the plant as follows: stem barks of A. leiocarpus were crushed and then an aqueous decoction was carried 
out. Exhaustion by the dichloromethane followed by dry evaporation (35°C) led to the extract of ALF used for the 
pharmacological investigations. The extract was prepared freshly in DMSO 100% then diluted in water in order to obtain a 
final concentration in the tank lower or equal to 0.02% (this concentration not having a notable effect on the activity of 
relieving, (Lugnier 2006).  
 
Cyclic nucleotide phosphodiesterase study 
 
PDE1, PDE3, PDE4 and PDE5 were isolated by anion exchange chromatography from bovine aortic smooth 
muscle cytosolic fraction according to Lugnier et al. (1986). PDE2 was isolated from human platelets following the method 
indicated in Kameni et al. (2001). Purified PDEs were stored until use at -80°C in small aliquots (200 µL). PDE activities 
were measured by radioenzymatic assay as previously described in detail (Thaseldar,) at a substrate concentration of 1 µM 
cAMP or 1 µM cGMP in the presence of 10,000 cpm [3H]-cAMP or [3H]-cGMP as tracers. The buffer solution was of the 
following composition: 50 mM Tris-HCl (pH 7.5), 2 mM magnesium acetate, 50 mg BSA. PDE1 was assayed at 1 µM 
cGMP in basal state (1 mM EGTA) or in calmodulin activated state (18 nM calmodulin with 10 µM CaCl2). PDE2 was 
evaluated at 1 µM cAMP + 1 mM EGTA in basal state (without 5 µM cGMP) and in activated state (in presence of 5 µM 
cGMP). PDE3 and PDE4 were assayed at 1 µM cAMP + 1 mM EGTA. To prevent the influence of reciprocal cross-
contamination between PDE3 and PDE4, the studies were always carried out in the presence of 50 µM rolipram (a generous 
gift of Schering, Berlin. Germany) for PDE3 and in presence of 50 µM cGMP for PDE4. PDE5 activity was measured at 1 
µM cGMP in the presence of 1 mM of EGTA. The concentration of compounds that produced 50% inhibition of substrate 
hydrolysis (IC50) was calculated by non-linear regression analysis (GraphPad Prism software, San Diego, Ca) from 
concentration-response curves including 6 different concentrations of inhibitors. The results were expressed as Means ± 
standard error of the mean (SEM) of at least three determinations in duplicate. 
 
Vascular reactivity studies 
 
Left anterior descending porcine coronary arteries (obtained from the local slaughterhouse) of either sex were 
cleaned of connective tissue and cut into rings (3–4 mm in length). As indicated the endothelium was removed by rubbing the 
intimal surface of rings with a pair of forceps. Rings were suspended in organ baths containing oxygenated (95% O2 and 5% 
CO2) Krebs bicarbonate solution (composition in mM: NaCl 119, KCl 4.7, KH2PO4 1.18, MgSO4 1.18, CaCl2 1.25, NaHCO3 
25, and D-glucose 11, pH 7.4, 37 °C) and the cyclooxygenase inhibitor indomethacin (10 μM), for the determination of 
changes in isometric tension. Following equilibration for 90 min under a resting tension of 5 g, rings were contracted with 
KCl (80 mM). After a 30 min washout period, rings were contracted with the thromboxane mimetic U46619 (1-3.10-8 M) to 
about 80% of the maximal contraction before addition of bradykinin (3.10-7 M) to check the presence of a functional 
endothelium. Rings were considered with and without endothelium when the relaxation to bradykinin is superior or equal to 
80% and inferior or equal to 0% respectively. After washout and a 30 min equilibration period, rings were again contracted 
with U46619 before construction of a concentration–relaxation curve to ALF. In some experiments, rings were exposed to an 
inhibitor for 30-45 min before the addition of U46619. 
 
Drugs and chemicals 
 
L-nitro-arginine (L-NA), 4-aminopyridine (4-AP), Charybdotoxine (CTX), Apanin (APA), Baryum (Ba2+), 
Ouabain, 1 H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ),  N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinoline 
sulfonamide dihydrochloride (H89) were all obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.).  U46619 (9,11-
dideoxy-11α, 9α-epoxymethanoprostaglandin F2α) was purchased from Cayman Chemical (Ann Arbor, MI, USA). 
 
Data and statistical analysis 
 
Rings from the same heart were used for one treatment only. Results are expressed as the Mean ± S.E.M. and n 
represents the number of rings used in the experiments. Relaxation was expressed as percentages of the U46619-induced 
contraction. IC50 and EC50 values were determined using a curve-fitting program (GraphPad prism 5.00.288). Two way 
analysis of variance (ANOVA) and post-hoc Bonferroni’s test were used to determine the significant differences between 
treatments. A P-value less than 0.05 was considered as statistically significant. 
 
 
 
 
 
Belemnaba et al., Afr J Tradit Complement Altern Med. (2013) 10(2):173-179 
http://dx.doi.org/10.4314/ajtcam.v10i2.1 
175
 
Results 
Effects of ALF extract on purified PDE1 to PDE5 
 
In vascular smooth muscle, cGMP degradation is mainly due to PDE1 which is activable by the calcium calmodulin 
complex, and  by PDE5 which specifically hydrolyses cGMP (Keravis et al;, 1980, Lugnier et al 1986,  Komas et al., 1991), 
whereas cAMP degradation is due to PDE3 and PDE4 (Lugnier et al., 1986, Komas et al., 1991, Orallo et al 2004). 
Endothelial cells, in opposite of smooth muscle cells does not contain PDE1 but PDE2 which hydrolyses both cAMP and 
cGMP and is activable by cGMP (Lugnier et Schini, 1990, Keravis et al., 2007). 
The dose-response of PDEs inhibition (Figure 1A-B) and Table I reporting the IC50 values of ALF for PDE1 to 
PDE5 show that ALF inhibited potently and preferentially cGMP degradation by PDE1 with an IC50 value of 1.6 ± 0.6 
µg/mL. In the same range (IC50 =2.8 ±0.2 µg/ml) ALF inhibited PDE2, a cGMP-activated enzyme that is only present in 
endothelial cells. PDE5, was also potently inhibited by ALF (IC50=7.6±3.5 µg/ml). The potencies of ALF on cAMP 
hydrolyzing isoenzymes was lesser, being more effective on PDE4 (IC50= 17.6±3.5 µg/ml) than on PDE3 (60.9 ± 1.8 µg/ml). 
These data clearly show that ALF preferentially inhibits the way of degradation of cGMP than those of cAMP.  
 
                                   A                                                           B 
 
 
 
Figure 1: Inhibition induced by cumulative concentrations of ALF on PDEs. (n= 3 duplicate different experiments, *p<0.05 
as compared with PDE 1, ANOVA follow by Bonferroni’s test ; (A). Histogram showed the IC50 statistical results 
of ALF activity on PDEs (B). (n = 3 different experiments, p<0.05 versus PDE 1, ANOVA with post-hoc 
Bonferroni’s test was use). 
 
 
Table I:  Effect of ALF on purified  vascular PDE1-PDE5 (IC50, µg/ml) 
 
    isoenzyme PDE1 PDE2 PDE3 PDE4 PDE5 
     3H Substrate cGMP cAMP cAMP cAMP cGMP 
Modulator CaM/Ca2+ + 5 µM cGMP - - - 
    IC50 (µg/mL) 1.6 ± 0.6 2.8 ± 0.2 60.9 ± 1.8 17.6 ± 3.5 7.1 ± 1.9 
 IC50 is defined as the concentration of the inhibitor (in µg/mL) required to reduce the cyclic nucleotide hydrolyzing 
activity of tested PDEs by 50%. Data represent the mean±s.e.m. of 3 independent experiments  
 
 
 
Table II: Effects of ALF on porcine coronary artery ((EC50, µg/ml)). 
 
 With 
endothelium (E) 
 
E+L-NA 
 
E+CTX+APA 
 
E+L-NA+CTX+APA 
Without 
endothelium 
 
   CE50 (µg/mL) 
 
2.3±1.0  
 
17.2 ± 2.3- 
 
2.1 ± 1.0  
 
18.8 ± 1.9 
 
11.5 ± 2.0 
ALF induced endothelium-dependant and endothelium-independent relaxation on porcine coronary artery 
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The endothelium-dependent vasorelaxant effects of ALF were examined on isolated porcine coronary artery rings 
with and without endothelium. Cumulative concentrations of ALF (0.1–100 µg/mL) produced concentration-dependent 
vasorelaxations both in endothelium-intact and endothelium-denuded artery rings. However, ALF induced a significant shift 
to the left in the response curve after endothelium denudation with significant increase in CE50 (from 2.3±1.0 to 11.5±2.0 
µg/ml), revealing that ALF-induced both endothelium-dependent and endothelium-independent vasodilatations (Figure 2, 
Tableau II). 
 
      
 
Figure 2 Left panel:Vasorelaxations induced by cumulative concentrations of ALF in endothelium-intact and endothelium-
denuded porcine coronary rings pre-contracted with U46619. ALF induced relaxant responses were significantly different in 
endothelium-intact and endothelium-denuded coronary rings at the indicated ALF concentrations. (n= 3 to 4 different 
experiments, *p<0.05). ANOVA follow by Bonferroni’s test. Figure 3 Right Panel: Concentration-responses curves of ALF 
induced relaxations in porcine coronary artery rings. Intact endothelium rings were contracted with U46619 before the 
addition of increasing concentrations of ALF. Rings with endothelium were also incubated with either Nω-nitro-L-arginine 
(L-NA, 300 μM, an inhibitor of eNOS), charybdotoxin (CTX, 100 nM) plus apamin (APA, 100 nM; two inhibitors of EDHF-
mediated relaxations) or the combination of L-NA plus CTX and APA for 30 min before addition of U46619. Experiments 
were performed in the presence of indomethacin. (n=3 to 4 different experiments. p< 0.05 versus control with endothelium 
was considered as significant, ANOVA follow by Bonferroni’s test). 
 
       
 
Figure 4: Concentration–response effect of ALF in U46619 pre-contracted endothelium-denuded coronary artery rings , or in 
the presence of N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide dihydrochloride (H89, 100nM) 
and 1H-[1,2,4]-Oxadiazole-[4,3-a ]-quinoxalin-1-one (ODQ, 10 µM) (A), or in the presence of the combination of 
H89 plus ODQ (B).(n= 3, *p<0.05 versus endothelium-denuded, ANOVA follow post-hoc Bonferroni’s test) 
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Figure 5: Without endothelium, rings were pre-incubated with 4-aminopyridine (4-AP, 1 mM), CTX (10µM) or Ba2+ 
(30µM) + ouabain (3 µM) (A) and with the association of 4-AP plus Ba2+ plus ouabain (B). All experiments were 
performed by the presence of indomethacin (10µM). (n=3 to 4 different experiments, *p<0.05 versus endothelium-
denuded, ANOVA follow by post-hoc Bonferroni’s test). 
 
Effects of NO and EDHF  
 
In endothelium-intact coronary rings, pretreatment with EDHF inhibitors (CTX plus APA) did not affect relaxation 
to ALF. But, pretreatment with a nitric oxide synthase (NOS) inhibitor L-NA or with both of them (L-NA plus CTX plus 
APA), significantly reduced the vasorelaxing effect of ALF (Figure 3). Therefore, the EC50 values (Table II) were in the same 
range with the EC50 value obtained in absence of endothelium, strengthening the endothelium dependent vasorelaxing effect 
of ALF. 
 
Modulation of ALF effects by PKA inhibitor and soluble Guanylyl cyclase inhibitor. 
 
In endothelium-denuded rings, this relaxant effect of ALF on the coronary tissues was not affected by the presence 
of H89 or ODQ alone (Figure 4 A). However, in the presence of H89 plus ODQ, the relaxation curve of ALF was slightly but 
significantly shifted suggesting a probable synergetic action of PKA and soluble guanylyl cyclase responsible to ALF 
relaxation (Figure 4B).  
 
 
Effects of potassium channel antagonists on ALF-induced of pig coronary arteries relaxation. 
 
ALF relaxation in endothelium-denuded rings was not affected by 4-aminopyridine (4-AP, a voltage-sensitive 
potassium-channel inhibitor) or charybdotoxin (CTX, an IKCa inhibitor) nor baryum (Ba2+) plus ouabain (an IK1 and Na+/K+-
ATPase inhibitors) (Figure 5 A). However, the addition of 4-AP plus Ba2+ plus ouabain leaded to a reduction of ALF 
maximal effect, in the order of 60% (Figure 5B). 
 
 
Discussion  
 
In this study, we demonstrated that the vasorelaxant effects of ALF is mediated via NO/sGC/cGMP and cAMP 
pathways, potassium (K+) and Na+/K+-ATPase channels opening. There are clear evidences from previous studies that 
NO/cGMP and cAMP pathways regulate vascular tone (Komas al. 1991; Lugnier and Komas 1993). Nitric oxide (NO) is an 
important regulator vascular function. The direct effect of NO on vascular tone is brought about by cGMP formation in 
vascular smooth muscles cells. Several NO-related compounds, such as sodium nitroprusside and endogenous NO activate 
soluble guanylate cylase (sGC), elevate cGMP and relax smooth muscles (Katsuki et al., 1977). 
The present findings indicate that ALF is a powerful endothelium-dependent vasodilator of porcine coronary 
arteries. Relaxations to ALF in endothelium-intact rings were significantly reduced by L-NA without affecting the maximal 
relaxation indicating an important role for NO. The inhibition of EDHF-mediated responses with charybdotoxin plus apamin 
did not affect relaxations to ALF.  In contrast to red wine extract (Ndiaye et al. 2005), the relaxation to ALF persisted in the 
presence of the combination L-NA, charybdotoxin and apamin on pig coronary artery. The persistent relaxation to ALF was 
not due to the formation of relaxing prostanoids; since all experiments were performed in the presence of indomethacin. The 
relaxation induced by ALF was significantly affected by disruption of the endothelial layer (5 fold increase in EC50), without 
being suppressed, suggesting that the site of action of ALF is in the vascular smooth muscle. Interestingly, ALF in the same 
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range of concentration inhibit PDE1 and PDE2, suggesting that in presence of endothelium both PDE1 and PDE2 were 
inhibited by ALF. 
Indeed, relaxation to ALF was not affected by the presence of a PKA inhibitor (H89) and an inhibitor of soluble 
guanylyl cyclase (ODQ) but their combination significantly reduced ALF relaxation in endothelium denuded artery 
suggesting a probable synergetic action of both of them. The relaxing effect of ALF may be also related to its ability to inhibit 
the activity of cAMP-phosphodiesterase (Ferrell et al., 1979). Vascular PDEs are differentially distributed in endothelial cells 
and vascular smooth muscle cells, and there is evidence of interaction between cGMP and cAMP degrading enzymes both in 
vascular endothelial and smooth muscle cells.  
The results showed that PDE1, 2, 4 and 5 were inhibited by ALF with IC50= 1.55 ± 0.56, 2.79 ± 0.23, 17.61 ± 3.50 
and 7.11 ± 1.90 µg/mL respectively. These results suggested that ALF may block the way of cGMP and cAMP degradation 
and then increase cAMP and cGMP level (Lugnier et al. 1999). These cyclic nucleotide accumulations may explain the 
relaxation mechanism of ALF on endothelium-intact and endothelium-denuded coronary artery rings. Our preliminary 
phytochemical screening identified some chemical compounds from ALF extract such as glycosides (sterols and triterpen) 
and alcaloides (Mann et al., 2009) which show a large variety of pharmacological action (Kim et al. 1999). It’s reported that 
some glycosides could inhibit cyclic nucleotide phosphodiesterase (Orallo et al. 2004). Hence, taken in conjunction with 
these results, ALF may activate the NO/sGC/cGMP and cAMP pathway and inhibit the PDEs activity, and therefore could 
elevate the intracellular cGMP and cAMP levels leading to vascular smooth muscle relaxation. 
On PDE3, the IC50= 60.85 ± 1.76 µg/mL of ALF was lower than the other PDEs inhibited but this result raised 
lightly significant inhibition. Several studies showed that PDE3 is present in vascular smooth muscle and is inhibited by 
cGMP and then increases cAMP (Beavo 1995; Lugnier et al. 1999; Mercapide et al. 1999; Sandner et al. 1999). Indeed, the 
nonspecific PDE inhibition activity may increase cAMP and cause relaxation in smooth muscles (Fischer et al. 1992). 
Moreover, a major focus of studies in vascular biology has been the role of the endothelium in modulating tone of vascular 
smooth muscle by the release of NO, stimulation of sGC, and the subsequent increase in intracellular cGMP (Lamping 2001). 
Although most of these studies suggest that vasorelaxation to many agents is mediated by the release of cGMP or cAMP 
alone, several of them have suggested that some “typical endothelium-independent” vasodilators may also release NO and 
activate sGC (Wang et al. 1993; Cardillo et al. 1997; Dawes et al. 1997). Thus, ALF relaxation in endothelium-denuded 
artery involves PDEs inhibition on vascular smooth muscle cells. 
To determine whether K+ channels mediated endothelium-independent relaxation of coronary rings by ALF, we 
used different potassium channel inhibitors. Pretreatment with 4-AP and CTX used only or Barium plus ouabain did not 
affect ALF-induced relaxation.  But this relaxation effect was markedly affected by the association of 4-AP plus Ba2+ plus 
ouabain and reduced maximal relaxation to about 60%. We suggested that ALF-induced vasorelaxation might be partly via 
the opening of voltage-dependent K+ channel (Kv), IK1 and Na+/K+- ATPase channels. 
In summary, these findings suggest that ALF activity on porcine coronary artery is endothelium-dependent and 
endothelium-independent. This is mostly on one hand, mediated via NO/sGC/cGMP pathway, stimulation of the K+, Na+/K+-
ATPase channels, on the other hand via inhibition of PDE activity and might contribute to explain the pharmacological effect 
of ALF. 
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